Joseph F. Goldberg, MD

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York

Back to top Open menu arrow
Early Career psychiatrists Authors and Reviewers Submit to JCP
JCP
Progression of Symptoms Over the Course of Bipolar Disorder
Insights

April 13, 2021

Dr Joseph F. Goldberg discusses how symptoms and clinical presentation change over time in people with bipolar disorder, beginning from the prodromal phase
JCP
ASCP Corner

January 19, 2021

The question of whether, and when, antidepressants are appropriate in bipolar disorder is a hotly debated topic. This ASCP Corner article summarizes the key concepts with greatest relevance for...
, ,
JCP
Editorial

January 12, 2021

This editorial discusses a recent study of citalopram in bipolar depression and revisits the long-held assumption that antidepressants lead to poor outcomes in bipolar disorder.
JCP
Identifying Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic
Academic Highlights

June 16, 2020

In this article focusing on maintenance treatment of bipolar I disorder, experts discuss functional impairment, the potential for LAI antipsychotics to address nonadherence, and the characteristics of patients who...
, , , et al
JCP
Commentary

June 2, 2020

This commentary discusses the findings of a recent study by Maccariello et al on the prevalence and predictors of switch to depression in bipolar patients who recently initiated or...
JCP
Commentary

April 7, 2020

During the COVID-19 pandemic, psychiatrists may respond to the "all hands on deck" call from health care institutions. This commentary looks at how expertise in distinguishing and managing normal...
JCP
Consensus Statement

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
, , , et al
JCP
Commentary

December 3, 2019

This commentary discusses the findings and implications of a recent post hoc study by Thase and colleagues on the utility of combinatorial pharmacogenomics in depression.
JCP
Educational Activity

July 30, 2019

New mechanisms of action present new opportunities to improve outcomes for patients with depression. Listen to a panel of experts discuss best practices and novel antidepressants at the 2019...
, , , et al
JCP
The Differential Diagnosis of MDD Versus BP
Academic Highlights

May 14, 2019

Given the similarity in clinical presentation between major depressive disorder (MDD) and the depressive episodes of bipolar disorder (BP), misdiagnoses occur too often. Read this Academic Highlights to learn...
, , , et al
JCP
ASCP Corner

October 30, 2018

Both undertreatment and futile overtreatment can be disastrous. How can clinicians find the right balance? This ASCP Corner article discusses related ethical and practical issues and then delineates the...
JCP
ASCP Corner

August 8, 2017

The potential for pharmacogenetic testing to help guide treatment is currently a hot topic within Psychiatry. In this ASCP Corner article, Joseph F. Goldberg considers whether the technology has...

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe